Ani Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect the seven director nominees named in the Proxy Statement to serve until the 2027 annual meeting and thereafter until their successors are elected and qualified.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm for the Year Ending December 31, 2026

   ManagementBoard: FOR

   Ratify the Audit and Finance Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory (Non-Binding) Vote to Approve the Compensation of the Company's Named Executive Officers

   ManagementBoard: FOR

   A non-binding, advisory 'say-on-pay' vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement, including the Compensation Discussion and Analysis and compensation tables.

   More detail

   This advisory (non-binding) 'say-on-pay' proposal asks stockholders to approve the compensation paid to the Company’s named executive officers as described in the proxy statement. Management seeks this advisory approval to validate its pay-for-performance philosophy, which ties significant compensation to both short-term corporate objectives and longer-term performance-based equity (PSUs and restricted stock), and to demonstrate alignment between executive incentives and shareholder value creation. Relevant context includes the Company’s strong 2025 financial performance (record net revenues and increased adjusted non-GAAP EBITDA), resulting in above-target payouts under the annual incentive plan and materially larger equity grants tied to multi-year EBITDA growth and relative TSR metrics. The Board highlights governance features intended to limit dilution and risk, including clawback provisions, double-trigger change-in-control protections, minimum vesting periods, limits on repricing, and director grant caps. Management frames the ask as routine and emphasizes prior stockholder support (89.6% approval in the prior year) and ongoing engagement with investors. Because the vote is advisory, its outcome will not mandate changes, but a negative result would prompt the Board and Compensation Committee to consider shareholder feedback and possibly adjust program design. The Board recommends a 'FOR' vote on the basis that current compensation structures have supported strong operational execution and align executive pay with long-term shareholder returns while incorporating risk-mitigating governance practices. The proposal therefore functions as a governance touchpoint that enables shareholders to express their view on pay without altering contractual obligations directly.

4. 4

   Advisory (Non-Binding) Vote to Approve the Frequency of Future Advisory Votes to Approve the Compensation of the Company’s Named Executive Officers

   ManagementBoard: FOR

   An advisory (non-binding) vote for stockholders to choose whether future say-on-pay advisory votes should be held every 1, 2, or 3 years (or abstain); the Board recommends a 1-year frequency.

   More detail

   This proposal asks shareholders to indicate, on a non-binding basis, how often the company should hold advisory 'say-on-pay' votes — once every 1, 2, or 3 years (or abstain). Management recommends an annual (1-year) frequency, arguing that annual votes provide the most timely and direct mechanism for shareholders to express views on executive pay and enable the Board and Compensation Committee to respond promptly to investor feedback. The proposal arises from Dodd-Frank requirements to solicit a frequency preference periodically and comes against a backdrop of active shareholder engagement and recent, sizable equity awards tied to both financial and TSR performance metrics. An annual frequency increases the cadence of governance feedback but does not change substantive compensation arrangements because all votes are advisory. If no single option receives a majority, the Board has stated it will consider the plurality result in making future decisions. The Company’s rationale balances transparency and responsiveness with administrative burden; management contends that the benefits of frequent stockholder input outweigh the incremental costs of annual voting. For investors evaluating the proposal, considerations include how quickly the company’s compensation program evolves, the degree of shareholder concern about pay practices, and whether more frequent votes produce meaningful changes in compensation policy. The Board’s endorsement of the 1-year option signals its willingness to receive frequent feedback and maintain accountability on pay matters, which may be viewed positively by governance-focused investors.

5. 5

   Approval of the Company's Amended and Restated 2022 Stock Incentive Plan

   ManagementBoard: FOR

   Approve the Amended and Restated 2022 Stock Incentive Plan to increase the number of shares available for issuance under the plan by 962,000 shares (bringing the total reserve to 8,222,000 shares upon approval).

   More detail

   This proposal asks shareholders to approve an amendment to the Company’s 2022 Stock Incentive Plan to add 962,000 shares to the plan reserve, increasing the total authorized share pool to 8,222,000 shares upon approval. Management’s stated rationale is workforce retention and competitiveness: the Company has used equity as a central element of compensation, including significant restricted stock and performance stock unit grants tied to multi-year EBITDA growth and relative TSR, and believes the current share reserve is insufficient to support future grants for executives, employees and non-employee directors. The proposal includes governance-minded guardrails — e.g., no discounted options, anti-repricing without shareholder approval, minimum vesting requirements (with limited exceptions), director grant caps, no evergreen provision, and limitations on dividend equivalents — which management highlights to limit dilution and protect shareholder interests. The proxy discloses recent burn-rate and overhang metrics, historical grant levels, and usage (2025 burn rate ~4.15% and overhang around 9–10%), allowing investors to evaluate dilution versus retention needs. Approving the increase would permit continued use of equity-linked incentives that align employee interests with long-term shareholder value, while opponents may focus on incremental dilution and whether alternative cash-based retention tools or more conservative equity usage should be prioritized. The Board recommends approval, arguing the amendment is necessary to sustain the Company’s compensation program and future talent needs while maintaining meaningful plan limits and governance features to mitigate shareholder dilution and preserve alignment. Investors evaluating the proposal should weigh the Company’s growth trajectory, recent equity utilization, and the plan safeguards against the potential dilutive impact of additional authorized shares.

Upcoming shareholder meetings at Ani Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Ani Pharmaceuticals Inc 2026 annual meeting?

Ani Pharmaceuticals Inc (ANIP) holds its 2026 annual shareholder meeting on Thursday, May 21, 2026.

What is the record date for the Ani Pharmaceuticals Inc 2026 meeting?

The record date for the Ani Pharmaceuticals Inc 2026 meeting is Monday, March 23, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Ani Pharmaceuticals Inc's 2026 meeting?

The board is presenting 7 director nominees at the Ani Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Ani Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 5 proposals at the Ani Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.